Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension-Reference-Cited by-同舟云学术

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension

Published:2021-01 Issue:1 Volume:159 Page:337-346
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Benza Raymond L.,Kanwar Manreet K.,Raina Amresh,Scott Jacqueline V.,Zhao Carol L.,Selej Mona,Elliott C. Greg,Farber Harrison W.

Funder

Janssen Pharmaceuticals

National Heart, Lung, and Blood Institute

National Institutes of Health

American Heart Association

Bayer

United States Food and Drug Administration

Instrumentation Laboratory Company

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference23 articles.

1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2. Assessing risk in pulmonary arterial hypertension: what we know, what we don’t;Benza;Eur Respir J,2017

3. Risk assessment tools in pulmonary arterial hypertension. Prognosis for prospective trials?;Farber;Am J Respir Crit Care Med,2018

4. The low-risk profile in pulmonary arterial hypertension. Time for a paradigm shift to goal-oriented clinical trial endpoints?;Weatherald;Am J Respir Crit Care Med,2018

5. Risk stratification and medical therapy of pulmonary arterial hypertension;Galiè;Eur Respir J,2019

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating biomarkers in pulmonary arterial hypertension: State-of-the-art review and future directions;JHLT Open;2024-11

2. Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study;The Journal of Heart and Lung Transplantation;2024-10

3. Clinical outcomes of upfront combination therapy for portopulmonary hypertension;International Journal of Cardiology Cardiovascular Risk and Prevention;2024-09

4. The evolution of the European risk stratification system for pulmonary arterial hypertension;European Respiratory Journal;2024-09

5. Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective;American Journal of Respiratory and Critical Care Medicine;2024-09-01